- A 68-year-old woman with a history of osteoporosis and newly diagnosed essential hypertension requires pharmacotherapy. Her physician considers initiating a diuretic. Which of the following agents would be most appropriate for this patient, considering both of her medical conditions?
Answer: Hydrochlorothiazide, as it increases calcium reabsorption in the distal convoluted tubule, reducing urinary calcium losses.
Thiazide diuretics, such as hydrochlorothiazide, inhibit the Na-Cl cotransporter in the distal convoluted tubule (DCT). This leads to a lower intracellular Na+ concentration, which enhances the activity of the basolateral Na+/Ca2+ exchanger, thereby increasing passive Ca2+ reabsorption through apical channels. The net effect is decreased renal calcium excretion (hypocalciuria), which can be beneficial for patients with osteoporosis. Furosemide (a loop diuretic) has the opposite effect; it increases calcium excretion and is not ideal for this patient.
- A patient with chronic hypertension managed with oral chlorthalidone presents to the emergency department with a blood pressure of 220/115 mmHg, respiratory distress, and bibasilar crackles on lung auscultation. In addition to intravenous antihypertensives, which modification to diuretic therapy is most appropriate?
Answer: Administer intravenous furosemide.
This patient is in a hypertensive emergency with signs of acute decompensated heart failure (pulmonary edema). This situation requires rapid and potent diuresis to reduce preload and relieve pulmonary congestion. Intravenous furosemide is the drug of choice because it has a rapid onset of action (within minutes) and is a potent diuretic capable of removing large fluid volumes. Oral diuretics are too slow-acting and less effective for this acute, life-threatening condition.
- The risk of diuretic-induced ototoxicity is significantly increased in a specific clinical context. Which of the following scenarios poses the greatest risk for this adverse effect?
Answer: A patient with acute renal failure receiving a high-dose intravenous bolus of furosemide.
When evaluating diuretic-induced ototoxicity risk, you need to consider both the specific drug class and the clinical circumstances that enhance toxicity potential. Loop diuretics like furosemide pose the highest ototoxicity risk, especially when administered rapidly at high doses intravenously.
Option A represents the perfect storm for ototoxicity: furosemide (a loop diuretic) given as a high-dose IV bolus to a patient with acute renal failure. The rapid IV administration creates dangerously high peak serum concentrations that can damage cochlear hair cells. Additionally, impaired renal function prevents normal drug clearance, prolonging exposure to toxic levels. This combination dramatically amplifies the risk of both temporary and permanent hearing loss.
Option B involves hydrochlorothiazide, a thiazide diuretic with minimal ototoxicity risk. While ACE inhibitors can enhance diuretic effects, neither drug significantly threatens hearing. Option C presents chlorthalidone, another thiazide with low ototoxic potential, given at low doses over time rather than as acute high-dose therapy. Option D involves torsemide, which is a loop diuretic, but it's given orally rather than IV, resulting in lower peak concentrations and reduced ototoxicity risk compared to IV administration.
The key pattern to remember: loop diuretics + rapid IV administration + high doses + renal impairment = maximum ototoxicity risk. Always be especially cautious when you see furosemide or bumetanide given intravenously at high doses, particularly in patients with compromised kidney function who cannot clear the drug effectively.
- A patient started on a diuretic for hypertension develops hypokalemia, hypomagnesemia, and hypocalcemia. Inhibition of which renal transporter is responsible for this specific constellation of electrolyte abnormalities?
Answer: The Na-K-2Cl cotransporter in the thick ascending limb.
Inhibition of the Na-K-2Cl cotransporter by loop diuretics (e.g., furosemide) in the thick ascending limb of the loop of Henle is responsible for this pattern. This inhibition disrupts the generation of the lumen-positive potential, which is the driving force for paracellular reabsorption of divalent cations like magnesium (Mg2+) and calcium (Ca2+). The result is increased urinary excretion and subsequent hypomagnesemia and hypocalcemia, in addition to the well-known hypokalemia.
- A patient presents with a chronic electrolyte pattern of hypokalemia, metabolic alkalosis, hypomagnesemia, and hypercalcemia. This laboratory profile is most analogous to the chronic pharmacologic effect of which class of antihypertensive agents?
Answer: Thiazide diuretics
This specific combination of electrolyte disturbances mirrors Gitelman syndrome, a genetic disorder involving a loss-of-function mutation in the Na-Cl cotransporter (NCC). This is the same transporter inhibited by thiazide diuretics. Chronic use of thiazides thus produces a phenocopy of Gitelman syndrome: hypokalemia and metabolic alkalosis (from volume contraction and increased distal Na+ delivery), hypomagnesemia, and characteristic hypercalcemia (due to enhanced Ca2+ reabsorption in the DCT). Loop diuretics would cause hypocalcemia.
- Both thiazide and loop diuretics can cause hyperuricemia and precipitate gouty attacks. This occurs primarily because these drugs interfere with which aspect of renal physiology?
Answer: They compete with uric acid for secretory transport via the organic anion transporters in the proximal tubule.
Diuretics are organic acids that are actively secreted into the proximal tubule by organic anion transporters (OATs). Uric acid is also secreted by these same transporters. Diuretics compete with uric acid for secretion, leading to a decrease in uric acid clearance and a subsequent rise in serum uric acid levels. Additionally, the volume depletion caused by diuretics enhances proximal tubule reabsorption of uric acid, further contributing to hyperuricemia.
- A 62-year-old man with hypertension and stage 4 chronic kidney disease (eGFR = 25 mL/min/1.73m²) has had a suboptimal blood pressure response to hydrochlorothiazide 25 mg daily. What is the most likely pharmacologic reason for the ineffectiveness of this therapy?
Answer: Secretion of hydrochlorothiazide into the tubular lumen via the organic anion transporter is insufficient.
Thiazide diuretics are organic acids that must be actively secreted into the proximal tubule lumen by the organic anion transporter (OAT) to reach their site of action in the distal convoluted tubule. In severe renal impairment (typically eGFR < 30 mL/min/1.73m²), the function of these transporters is diminished, leading to inadequate drug concentrations at the target site and thus reduced efficacy. While compensatory mechanisms occur, the primary reason for ineffectiveness in severe CKD is impaired drug delivery to the site of action.
- A patient being treated with high-dose furosemide for hypertension associated with heart failure presents with profound muscle weakness and constipation. An ECG reveals prominent U waves. These findings are most directly caused by the diuretic's effect on which transporter and resulting electrolyte abnormality?
Answer: Inhibition of the Na-K-2Cl cotransporter leading to hypokalemia.
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. This action leads to significant potassium wasting and subsequent hypokalemia. The clinical manifestations of severe hypokalemia include muscle weakness, constipation (due to smooth muscle dysfunction), and characteristic ECG changes such as prominent U waves, T wave flattening, and ST depression.
- A patient on chronic high-dose furosemide therapy exhibits a progressively diminishing response, a phenomenon known as diuretic braking or resistance. Which compensatory physiological change in the nephron is the primary driver of this effect?
Answer: Hypertrophy of distal convoluted tubule cells with increased expression of the Na-Cl cotransporter.
Chronic blockade of sodium reabsorption in the loop of Henle by furosemide leads to an increased delivery of sodium to the distal nephron. This chronic increase in solute load stimulates a compensatory hypertrophy and hyperplasia of cells in the distal convoluted tubule (DCT). These hypertrophied cells exhibit increased numbers of Na-Cl cotransporters (NCC), leading to enhanced sodium reabsorption at this site, which partially counteracts the effect of the loop diuretic upstream.
- Long-term therapy with a thiazide or loop diuretic for hypertension characteristically leads to a mild metabolic alkalosis. This acid-base disturbance is primarily the result of which two concurrent mechanisms?
Answer: Volume contraction-induced activation of RAAS and increased distal tubular H⁺ secretion.
Metabolic alkalosis from these diuretics is multifactorial. First, the diuretic-induced volume contraction activates the renin-angiotensin-aldosterone system (RAAS). Increased aldosterone stimulates H⁺ secretion via the H⁺-ATPase in the intercalated cells of the collecting duct. Second, the increased delivery of Na⁺ to the distal tubule enhances Na⁺ reabsorption via ENaC, creating a lumen-negative potential that drives secretion of both K⁺ and H⁺. The combination of volume contraction and K⁺/H⁺ loss results in a net gain of bicarbonate and metabolic alkalosis.
- For the initial management of a patient with uncomplicated primary hypertension, a thiazide diuretic like hydrochlorothiazide is often preferred over a loop diuretic like furosemide. What is the primary pharmacokinetic and pharmacodynamic rationale for this choice?
Answer: Thiazides have a longer duration of action, which provides more consistent 24-hour blood pressure control.
Thiazide diuretics have a longer half-life and duration of action (e.g., HCTZ: 12-18 hours; chlorthalidone: 24-72 hours) compared to loop diuretics (e.g., furosemide: 4-6 hours). This longer duration provides smoother, more sustained blood pressure control throughout the day with once-daily dosing. The potent, short-acting diuresis from furosemide can lead to more significant volume depletion and stronger activation of compensatory mechanisms (like RAAS), making it less ideal for chronic, stable hypertension management.
- A 55-year-old patient stabilized on chlorthalidone for hypertension begins taking ibuprofen 600 mg three times daily for osteoarthritis. Over the next two weeks, her home blood pressure readings are consistently elevated. Which mechanism best explains this drug interaction?
Answer: Ibuprofen inhibits renal prostaglandin synthesis, leading to afferent arteriole vasoconstriction and reduced renal blood flow.
NSAIDs, like ibuprofen, inhibit cyclooxygenase (COX) enzymes, which reduces the synthesis of renal prostaglandins (e.g., PGE2, PGI2). These prostaglandins are crucial for maintaining renal blood flow and glomerular filtration rate, particularly in the context of diuretic-induced volume contraction. By inhibiting these vasodilatory prostaglandins, NSAIDs cause afferent arteriole vasoconstriction, reduce renal blood flow, and blunt the natriuretic and antihypertensive effects of diuretics.
- A patient with hypertension is prescribed combination therapy with lisinopril and hydrochlorothiazide. What is the most significant synergistic advantage of this combination with respect to electrolyte homeostasis?
Answer: The kaliuretic effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of lisinopril.
Hydrochlorothiazide increases potassium excretion, leading to a risk of hypokalemia. Lisinopril, an ACE inhibitor, blocks the production of angiotensin II and subsequently aldosterone. Reduced aldosterone levels decrease the activity of sodium channels (ENaC) and potassium channels (ROMK) in the collecting duct, leading to decreased potassium secretion (a potassium-sparing effect). When used together, these opposing effects on potassium handling help to maintain serum potassium within the normal range.
- Based on the laboratory data provided, which of the following best describes the patient's acid-base and electrolyte status?
Answer: Hypokalemic, hypochloremic metabolic alkalosis with hypercalcemia.
When analyzing a patient on thiazide diuretics like hydrochlorothiazide, you should systematically evaluate electrolytes and acid-base status, as these medications have predictable effects on renal handling of ions.
Let's interpret each lab value. Potassium at 3.2 mEq/L indicates hypokalemia (normal: 3.5-5.0). Chloride at 91 mEq/L shows hypochloremia (normal: 98-107). Bicarbonate at 32 mEq/L reveals metabolic alkalosis (normal: 22-28). Calcium at 10.9 mg/dL indicates hypercalcemia (normal: 8.5-10.5). This constellation fits perfectly with thiazide effects: they block sodium-chloride reabsorption in the distal tubule, causing sodium and chloride loss, while promoting calcium retention and potassium wasting through compensatory aldosterone activation.
Answer A correctly identifies all abnormalities: hypokalemic, hypochloremic metabolic alkalosis with hypercalcemia. This matches the expected thiazide toxidrome.
Answer B incorrectly states the patient is normokalemic and normochloremic, missing the clear hypokalemia and hypochloremia. It also incorrectly suggests hypocalcemia when calcium is elevated.
Answer C misidentifies the acid-base disorder as metabolic acidosis rather than alkalosis, despite the elevated bicarbonate clearly indicating alkalosis. It also incorrectly states hyperchloremic when chloride is low.
Answer D incorrectly suggests hyperkalemia (opposite of what thiazides cause), metabolic acidosis instead of alkalosis, and normocalcemia despite the elevated level.
Study tip: Remember "thiazides cause the four Hs": Hypokalemia, Hypochloremia, Hypercalcemia, and High bicarbonate (metabolic alkalosis). This pattern will help you quickly recognize thiazide-related electrolyte disturbances.
- A patient with hypertension requires a diuretic but reports a history of Stevens-Johnson syndrome after taking trimethoprim-sulfamethoxazole. Which statement most accurately reflects the clinical considerations for diuretic selection?
Answer: While most loop and thiazide diuretics are sulfonamide derivatives, evidence for cross-reactivity is limited, but a non-sulfonamide option like ethacrynic acid exists.
Most thiazide (e.g., HCTZ) and loop diuretics (e.g., furosemide, bumetanide) contain a sulfonamide moiety. However, they are structurally different from sulfonamide antibiotics. While caution is warranted, the risk of cross-reactivity between sulfonamide antibiotics and non-antibiotic sulfonamides is considered very low. For a patient with a severe reaction like SJS, the most prudent approach is to acknowledge the theoretical risk and consider a non-sulfonamide diuretic if possible. Ethacrynic acid is a loop diuretic that lacks a sulfonamide structure and is the classic alternative in this scenario.
- Chlorthalidone is often preferred over hydrochlorothiazide for hypertension management based on evidence from major clinical trials. This preference is primarily attributed to which pharmacologic property of chlorthalidone?
Answer: A significantly longer plasma half-life and duration of action, ensuring more consistent BP control.
The primary reason for chlorthalidone's superior performance in some hypertension trials is its pharmacokinetic profile. It has a much longer half-life (40-60 hours) compared to hydrochlorothiazide (8-15 hours). This results in more sustained and consistent 24-hour blood pressure reduction, including better nocturnal blood pressure control, which is thought to contribute to improved cardiovascular outcomes. Both drugs have similar metabolic side effect profiles and are sulfonamide derivatives.
- A 58-year-old man with type 2 diabetes and hypertension, previously well-controlled on metformin, was started on chlorthalidone. Six months later, his HbA1c has risen significantly. The primary mechanism for this thiazide-induced hyperglycemia involves:
Answer: Inhibition of potassium channels in pancreatic β-cells, which impairs insulin secretion.
Thiazide diuretics can cause hypokalemia. Potassium is critical for insulin secretion from pancreatic β-cells. Depletion of intracellular potassium leads to hyperpolarization of the β-cell membrane, which reduces the activity of voltage-gated calcium channels. This, in turn, decreases calcium influx and impairs the glucose-stimulated release of insulin. The resulting reduction in insulin secretion contributes to hyperglycemia.
- The thiazide-like diuretic indapamide is thought to have an antihypertensive mechanism that extends beyond its effect on the Na-Cl cotransporter. What additional property contributes to its vasodilatory and blood pressure-lowering effects?
Answer: Inhibition of calcium influx through voltage-gated calcium channels.
In addition to its diuretic action in the kidney, indapamide has been shown to have direct vasodilatory effects. This is attributed, in part, to its ability to inhibit calcium influx through L-type voltage-gated calcium channels in vascular smooth muscle cells. This action reduces intracellular calcium concentration, leading to smooth muscle relaxation, decreased peripheral vascular resistance, and a further reduction in blood pressure, distinguishing it from other thiazides like HCTZ.
- A patient with hypertension also has severe peripheral edema due to systolic heart failure. While a thiazide diuretic may contribute to blood pressure control, a loop diuretic is generally required. What is the principal reason for preferring a loop diuretic in this setting?
Answer: Loop diuretics possess a significantly higher capacity for solute and water excretion.
When you encounter a patient with both hypertension and heart failure with severe edema, you need to understand the fundamental differences in diuretic potency and clinical applications.
Loop diuretics like furosemide work at the thick ascending limb of the loop of Henle, blocking the Na-K-2Cl cotransporter. This mechanism allows them to excrete up to 20-25% of filtered sodium, making them the most potent diuretics available. In contrast, thiazide diuretics work at the distal convoluted tubule and can only excrete about 5-10% of filtered sodium. When a patient has severe peripheral edema from systolic heart failure, you need maximum fluid removal capacity - this is why option A is correct.
Option B is incorrect because thiazide diuretics don't have paradoxical antidiuretic effects in heart failure patients. Option C reverses the truth - loop diuretics actually cause more electrolyte wasting than thiazides, particularly potassium and magnesium, which is why careful monitoring is essential. Option D overstates the case; while RAAS activation in heart failure can reduce thiazide effectiveness, they don't lose "all efficacy."
The key principle here is matching diuretic potency to clinical need. Mild hypertension might respond to thiazides, but severe volume overload requires the superior natriuretic capacity of loop diuretics.
Study tip: Remember the "power hierarchy" of diuretics: loop > thiazide > potassium-sparing. For boards, when you see severe edema or heart failure, think loop diuretics first for their unmatched ability to mobilize large volumes of fluid.
- A clinician argues that furosemide should be superior to hydrochlorothiazide for essential hypertension due to its much higher diuretic ceiling. Why is this reasoning flawed for the long-term management of uncomplicated hypertension?
Answer: The short, intense diuresis from furosemide leads to stronger counter-regulatory responses and less stable 24-hour BP control.
While loop diuretics are more potent diuretics (higher ceiling), this doesn't translate to better chronic antihypertensive efficacy. The rapid and profound diuresis caused by short-acting agents like furosemide leads to abrupt volume changes, which triggers a more robust activation of compensatory systems (e.g., RAAS, sympathetic nervous system). This, combined with its short half-life, results in periods of sodium retention between doses and less consistent blood pressure control compared to the milder, longer-acting profile of thiazides.
